Carl A Shirley
Overview
Explore the profile of Carl A Shirley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volety P, Shirley C, Chhabra G, Ahmad N
Photochem Photobiol
. 2024 Apr;
100(4):910-922.
PMID: 38623955
Metastatic melanoma is an aggressive skin cancer with high mortality and recurrence rates. Despite the clinical success of recent immunotherapy approaches, prevailing resistance rates necessitate the continued development of novel...
2.
Miranda A, Shirley C, Jenkins R
Trends Cancer
. 2024 Mar;
10(6):531-540.
PMID: 38519366
TANK-binding kinase 1 (TBK1) is a versatile serine/threonine protein kinase with established roles in innate immunity, metabolism, autophagy, cell death, and inflammation. While best known for its role in regulating...
3.
Shirley C, Chhabra G, Amiri D, Chang H, Ahmad N
Front Immunol
. 2024 Mar;
15:1336023.
PMID: 38426087
Melanoma is one of the most lethal neoplasms of the skin. Despite the revolutionary introduction of immune checkpoint inhibitors, metastatic spread, and recurrence remain critical problems in resistant cases. Melanoma...
4.
Chhabra G, Singh C, Ndiaye M, Su S, Shirley C, Ahmad N
NPJ Precis Oncol
. 2024 Jan;
8(1):6.
PMID: 38184733
Polo-like kinase 1 (PLK1), a serine/threonine kinase, is overexpressed in melanoma and its expression has been associated with poor disease prognosis. PLK1 has been shown to interact with NUMB, a...
5.
Thornton J, Chhabra G, Singh C, Guzman-Perez G, Shirley C, Ahmad N
Front Oncol
. 2022 May;
12:880876.
PMID: 35515106
Melanoma is one of the seven most common cancers in the United States, and its incidence is still increasing. Since 2011, developments in targeted therapies and immunotherapies have been essential...